🏆 #1 Cancer Screening Innovation | $300 vs $949 Leading Competitors* | 100% NPV in Current Study** | Presenting at Washington D.C. Summit 2025
CONFERENCE ANNOUNCEMENT

Presenting at Next Generation Dx Summit 2025

Join UCM Technologies at the premier diagnostics conference showcasing our groundbreaking CA-62 cancer screening research

August 18-20, 2025
Presentation Day
Washington D.C.
Capital Hilton
900+ Attendees
Industry Leaders
Limited Conference Slots Available - Book Your Meeting Now
Book exclusive meeting with UCM CEO See UCM Advantages

UCM Technology Advantages

CA-62 uniquely detects cancer, pre-cancerous conditions (adenomas), and acute inflammatory conditions (ulcers, sarcoidosis) through low differentiated cells production increase - our key distinguisher from competitors

88-94%
Superior Early Detection
vs Leading Competitors' 27.5% early-stage sensitivity*
$300
68% Cost Savings
Other tests cost $949 per test
100%
Superior Reliability*
100% NPV* vs Leading Competitors' 98.5% NPV*
B2B
Business-Ready
Built for corporate wellness & insurance
2025
Latest Innovation
Next Generation Dx Summit Validation

💰 CA-62 ($300) vs Leading Competitors ($949) - Annual Savings Calculator

Quick Cost Comparison Examples

1,000 Employees
CA-62: $300K | Others: $949K
Save $649K annually
500 Employees
CA-62: $150K | Others: $474.5K
Save $324.5K annually
100 Employees
CA-62: $30K | Others: $94.9K
Save $64.9K annually
💰 Total Annual Savings with CA-62 vs Leading Competitors: $649,000
CA-62 at $300/test vs leading competitors at $949/test + reduced biopsies ($15K each) + superior early-stage detection*
View Savings Calculator

Latest Research Findings

Results from our groundbreaking CA-62 pilot study with 1,005 participants demonstrate exceptional cancer detection capabilities

Important Scientific Disclaimers

Study Context: Results based on pilot study of 1,005 participants. Numbers like 100% NPV and sensitivity ranges are study-specific and may vary in larger populations. Important: No medical test achieves perfect accuracy; these results represent current study performance and individual results may vary.

Not Diagnostic: CA-62 is currently a wellness test, not approved for diagnostic use by regulatory agencies.

Comparative Claims: Competitor comparisons marked with * require additional validation studies for regulatory approval.

Study Population

1,005 Asymptomatic Employees

Comprehensive screening of at-risk population over 45 years with documented occupational cancer exposure.

🎯 Perfect for corporate wellness programs

Negative Predictive Value

100% Perfect NPV

No patients with no cancers tested positive for CA-62 and none of the CA-62 negative patients were found to have cancer on further clinical testing.

✅ Zero false negatives in current study* - Industry leading accuracy

Sensitivity Range

88-94% At 95% Specificity

Outperforms all known cancer screening tests especially for asymptomatic early stage cancers with excellent specificity for clinical deployment.

📊 Prospective study design (more valuable than retrospective)

Cancer Detection

11/11 All Cancers Detected*

Successfully identified all cancer cases including various types: lymphoma, carcinomas, melanoma, and leukemia.

🏆 Perfect detection record

Cancer Types Detected by CA-62 Screening

Study Results Overview: Cancer, Benign & Pre-Cancerous Conditions Identified

1,005
Total Screened
63
CA-62 Positive (6.2%)
11
Confirmed Cancers
23
Benign Conditions
Comprehensive detection includes cancers, adenomatous polyps (pre-cancerous), and acute inflammatory conditions out of 1,005 total participants

Scientific References

¹ Sensitivity range based on prospective study of 1,005 asymptomatic participants at 95% specificity threshold

² Negative Predictive Value: No participants with negative CA-62 results were subsequently diagnosed with cancer during clinical follow-up

Study Design: Pilot cancer screening study using CA-62 biomarker - prospective design with comprehensive clinical follow-up

Scientific Publications & Regulatory Status

Current research status, ongoing studies, and regulatory pathway for CA-62 technology

Current Study Status

Pilot Study Completed

Initial pilot study with 1,005 participants has been completed. Results presented at medical conferences for peer review and validation.

📊 Conference presentations ongoing

Regulatory Pathway

Phase I Wellness Testing

Currently positioned as wellness test. Regulatory approval pathway being developed for diagnostic applications with health authorities.

⚠️ Not yet diagnostic approved

Publication Pipeline

In Progress Peer Review

Manuscript preparation in progress for submission to peer-reviewed medical journals. Conference abstracts and posters available for scientific community review.

📝 Journal submissions planned 2025

Conference Presentations

2025 NGDx Summit

Research findings being presented at Next Generation Dx Summit 2025 in Washington D.C. for peer review and feedback from diagnostics community.

🎯 August 18-20, 2025 presentation

Research Transparency & Context

1,005
TOTAL PARTICIPANTS

Complete study population providing context for all reported percentages and statistical measures

63
CA-62 POSITIVE (6.2%)

Participants with positive CA-62 results, providing denominator for specificity calculations

11
CONFIRMED CANCERS

Actual cancer cases from the 63 CA-62 positive results (27.5% PPV rate)

Creating Faster, More Accurate Solutions in Early Cancer Screening

UCM Technologies is at the forefront of cancer detection innovation, developing the revolutionary CA-62 test - a comprehensive, non-invasive, highly-sensitive early stage cancer screening solution.

Our Universal Cancer Marker (UCM) Technology represents a paradigm shift in cancer screening, offering 90+% sensitivity for stage I&II epithelial cancers (ovarian, pancreatic, colorectal, prostate) while eliminating the need for invasive, costly biopsy procedures.

With our pilot study of 1,005 participants completed across multiple regions, our CA-62 technology demonstrates promising results and is being prepared for larger-scale validation studies to support regulatory approval.

Learn About CA-62 Testing
Medical Laboratory Research

CA-62 Testing Technology

Advanced biomarker technology for early cancer detection with proven clinical results

Important Medical Disclaimers

Blood Sample Requirement: CA-62 requires a blood sample for testing.

Regulatory Status: CA-62 is a wellness test and is not currently approved for diagnostic use by Health Canada or the FDA.

Study Limitations: 100% sensitivity for cancer in our current study does not preclude the possibility of false negatives in future studies. CA-62 performance may vary in different populations and clinical settings. This test is designed to complement, not replace, standard screening methods.

No Biopsy Required

Avoids invasive, costly, and infection-risky biopsy procedures. Reduces false positives associated with biopsies (1 in 5 biopsies return false positive).

Increased Sensitivity

Identifies a small cohort of uninsurable clients with high accuracy, enabling more precise risk assessment. Potentially impacts up to 480,000 cases across North America.

Proven Medical Technology

Offers promising accuracy compared to standard tests in pilot study. Currently validated in 1,005-participant study across North America, with larger validation studies planned.

Wellness First Approach

Engages consumers with less-invasive proactive screening, fostering greater receptivity to health management and early intervention.

Innovative Technology

Advanced biomarker detection using low differentiated cells production increase methodology. Reduces costs and workload in labs while minimizing false positives with our reliable screening tool.

Wider Testing Reach

Simple and less-invasive nature makes it suitable for group benefit plans and executive wellness assessments across diverse populations.

For Businesses & Insurers

Advanced CA-62 biomarker technology delivers superior accuracy with comprehensive risk assessment capabilities for corporate wellness programs.

💰 Strategic Cost Management

$300
Per Test Investment

Comprehensive screening at $300 per test with 88-94% sensitivity¹ and 100% NPV² in current study. May help reduce downstream medical costs through early detection and intervention, though individual results may vary and test performance may differ in larger populations.*

Volume discount available for 1,000+ employees

📈 Business Impact

480,000
Potential Cases North America

Scale your wellness programs effectively. Simple deployment for group benefit plans and executive assessments.

✅ Immediate deployment capability

⚡ Operational Efficiency

75%
Reduction in Follow-ups

Screen-and-retest protocol filters transient results. Focus resources on cases that matter most.

🎯 Streamlined workflow integration

🏆 Why UCM Technology Appeals to Business Leaders

💰 Superior Value Proposition

CA-62 delivers exceptional clinical performance at $300 per test. Advanced biomarker technology provides comprehensive health insights beyond cancer screening, including pre-cancerous and inflammatory condition detection.

Immediate Implementation

Unlike leading competitors requiring months of setup, UCM integrates into existing wellness programs in weeks. Testing to be performed in CLIA-Certified and CAP-Accredited laboratories. Ready for corporate deployment at $300/test.

Dual Value Creation

Detect cancer early AND identify inflammatory conditions affecting productivity. Potential medical cost benefits at lower cost than leading competitors*.

⚠️ Important Medical Considerations

Test Performance: While CA-62 shows promising results in our pilot study, no medical test achieves perfect accuracy. Results may include false positives and false negatives. Test performance may vary in different populations and clinical settings. Always consult healthcare professionals for interpretation and follow-up care decisions.

Executive Decision Support

Clear ROI metrics showing $649K annual savings per 1,000 employees, direct conference access to leadership team, and transparent cost-benefit reporting for board presentations.

Schedule Executive Briefing Request ROI Analysis
Biotech Scientist

🎯 Secure Your Competitive Advantage

Book an exclusive meeting with UCM Technologies leadership at NGDx Summit 2025

⏰ Only 20 meeting slots available | 12 already booked
💰 Discuss how $300/test could save your company $649K annually vs leading competitors*

Conference Meeting Request

Contact UCM Technologies

Get in touch with our team for more information about CA-62 technology and partnerships

Research Contact

Evgueni Klinski
Lead Researcher
evgueni.k@ucmtechnologies.com
+1 (514) 898-2931

Corporate Headquarters

8000 Jane Street, Tower A, Suite 101
Concord, ON L4K 5B8
Canada
Medical Technology Innovation
Book Meeting Why UCM